US Endovascular and BrosMed enter into exclusive agreement to distribute coronary angioplasty catheters

439

US Endovascular and BrosMed have entered into an exclusive agreement to distribute Artimes semi-compliant and Apollo non-compliant coronary angioplasty catheters.

Apollo is a non-compliant high pressure post-dilatation catheter, which offers a folded balloon for crossibility, flexibility and balloon rewrap, a spiral extrusion catheter and a low crossing profile for enhanced robust and non-compliant balloon. The device is extraordinary minor (3%) axial growth and 5F guiding catheter compatible with balloon sizes 2–5mm and lengths of 8–18mm. Average burst pressure is 30atm.

Artimes is a semi-compliant pre-dilation catheter which also offers a folded balloon for crossibility, flexibility and balloon rewrap, a spiral extrusion catheter and a low crossing profile to facilitate the physician and procedure. Balloon sizes are designed for tight lesions and treatment of chronic total occlusions.

BrosMed and US Endovascular have entered the US coronary angioplasty market with a goal of “providing high quality more affordable coronary angioplasty catheters to hospitals, physicians and the patients they treat,” says a press release.

John McCurdy, president and chief executive officer of US Endovascular commented, “the relationship with a world-class organisation like BrosMed will add significant value to our customer partners and strengthen our emerging position in the US market. We are thrilled to be working with BrosMed and are impressed with their commitment to provide the highest quality products in the USA.”

“BrosMed management has a long history in the international marketplace and is proud of its quality and production system as we ready for a US market launch. We expect that this long-term agreement with US Endovascular will benefit both our strategies”, notes Benny Lee, chief executive officer of BrosMed.

“This is a significant step forward for BrosMed to increase global sales, and to seek US Food and Drug Administration approval for additional coronary and peripheral endovascular devices that will include advanced technology,” says Jos De Korte, vice president sales and marketing and general manager of BrosMed Medical BV Netherlands.

(Visited 110 times, 1 visits today)